Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhert...
27 April 2021 - 10:05PM
Business Wire
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic
collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue
regulatory approval and commercialization of the Guardant360® CDx
blood test as a companion diagnostic for Enhertu® (fam-trastuzumab
deruxtecan-nxki), a HER2-directed antibody-drug conjugate (ADC),
being studied in the treatment of patients with advanced metastatic
non-small cell lung cancer (NSCLC).
“For patients with metastatic non-small cell lung cancer,
personalized medicines targeting actionable mutations, as revealed
by our Guardant360 liquid biopsy test, have been life-changing,”
said Helmy Eltoukhy, Guardant Health CEO. “Such medicines may
extend overall survival for many patients, and we are excited to
work with Daiichi Sankyo, as there remains an unmet medical need to
help non-small cell lung cancer patients with HER2 mutations.”
The Guardant360 CDx test is FDA-approved to provide
comprehensive genomic profiling results to guide treatment in all
solid tumors, including NSCLC. Sequencing a broad number of genes
to understand the molecular drivers of a patient’s cancer is
critical, as the number of treatment-relevant genomic alterations
continues to grow.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
blood tests, vast data sets, and advanced analytics. The Guardant
Health oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes, and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched liquid biopsy-based Guardant360®,
Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer
patients, and Guardant Reveal™ test for early-stage cancer
patients. These tests fuel development of its LUNAR screening
program, which aims to address the needs of asymptomatic
individuals eligible for cancer screening and individuals at a
higher risk for developing cancer with early detection.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential scope, impact or benefit of Guardant Health
liquid biopsies which involve risks and uncertainties that could
cause the actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking
statements. These statements are based on current expectations,
forecasts and assumptions, and actual outcomes and results could
differ materially from these statements due to a number of factors.
These and additional risks and uncertainties that could affect
Guardant Health’s financial and operating results and cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release include those
discussed under the captions “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operation” and elsewhere in its Annual Report on Form 10-K for the
year ended December 31, 2020 as well as in its other reports filed
with the Securities and Exchange Commission, including, when filed,
its Quarterly Report on Form 10-Q for the period ended March 31,
2021. The forward-looking statements in this press release are
based on information available to Guardant Health as of the date
hereof, and Guardant Health disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Guardant Health’s views as of any date subsequent to
the date of this press release.
Source: Guardant Health, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210427005136/en/
Investor Contact: Carrie Mendivil
investors@guardanthealth.com
Media Contact: Anna Czene press@guardanthealth.com
Julie Johnson julie.johnson@uncappedcommunications.com
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Apr 2024 to May 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From May 2023 to May 2024